FIELD: medicine.
SUBSTANCE: provides a method of assessing susceptibility of a subject to occurrence of prostate cancer which includes determination of level of MR-pro-ADM, MR-pro-ANP and copeptin fragments with length of at least 12 amino acids and correlation of said level of fragments with a risk of prostate cancer occurence in a subject, wherein subject has not yet been diagnosed as one that has cancer and / or does not have cancer. If MR-pro-ANP level is lowered and / or when MR-pro-ADM and / or copeptin level is increased, subject sensitivity to prostate cancer is defined.
EFFECT: invention provides efficient evaluation of subject sensitivity to prostate cancer occurence.
14 cl, 1 dwg, 8 tbl, 1 ex
